• Vera Therapeutics named Nancy Bowman, M.D., Ph.D., as chief regulatory officer, effective Aug. 3, 2026.
• William Turner will step down as chief regulatory officer on Aug. 3, 2026, shifting to special advisor for regulatory affairs.
• The changes were announced July 9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-299165), on July 09, 2026, and is solely responsible for the information contained therein.